Dxcover Limited is a Scottish company which was founded on 16 May 2016. It is based in

Glasgow Glasgow is the Cities of Scotland, most populous city in Scotland, located on the banks of the River Clyde in Strathclyde, west central Scotland. It is the List of cities in the United Kingdom, third-most-populous city in the United Kingdom ...

, UK. It combines novel hardwares with

artificial intelligence Artificial intelligence (AI) is the capability of computer, computational systems to perform tasks typically associated with human intelligence, such as learning, reasoning, problem-solving, perception, and decision-making. It is a field of re ...

algorithms. Patients' blood samples are analysed by scientists to detect the presence of diseases. It is a clinical stage

liquid biopsy A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for ...

company and uses artificial intelligence algorithms for early detection of cancers and other diseases to improve survival rates. Its marketplaces are located in the US, UK and EU. The company aims to detect early stage (Stage I and Stage II) of cancers.

History

The company was previously named as ClinSpec Diagnostics Limited between 16 May 2016 and 26 April 2021. It is spun out from the

University of Strathclyde The University of Strathclyde () is a public research university located in Glasgow, Scotland. Founded in 1796 as the Andersonian Institute, it is Glasgow's second-oldest university, having received its royal charter in 1964 as the first techn ...

, Glasgow. After that, it is rebranded as Dxcover Limited in 2021.

Technology

Dxcover has developed 'Drop, Dry, Detect' technology which technically detects and works in minutes to detect signs of cancer using artificial intelligence trained model. Panoramic platform is a multi-omic spectral analysis (MOSA) technology for various cancers which are brain, advanced adenoma, colorectal, and lung cancer. This technology analyses the signals that were missed by traditional cancer detection methods. For brain tumors, there is no biomarker test available. The test algorithm makes use of the complete biological profile of the patient's serum sample rather than concentrating on a single biomarker for illness. Results are accessible in minutes, and no specialized sample preparation is needed.

Funding

Based on research conducted at Strathclyde University, Dxcover Limited has raised over £10 million for its technology that enables the early diagnosis of numerous malignancies. Existing investors lead by Eos Advisory LLP contributed £7.5 million in Series A funding, with further contributions from the University of Strathclyde, Mercia Fund Management, Scottish Enterprise, Social Investment Scotland Ventures, and Norcliffe Capital. As Dxcover continues to expand its U.S. network, Boston-based life science investor Mark Bamforth of Thairm Bio also joined the round.{{Cite web , title=Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers {{! University of Strathclyde , url=https://www.strath.ac.uk/whystrathclyde/news/2023/dxcoverraises10mtodeveloppioneeringliquidbiopsyplatformforearly-stagecancers/ , access-date=2024-06-07 , website=www.strath.ac.uk The

European Innovation Council The European Innovation Council (EIC) was introduced by the European Commission to support the commercialization of high-risk, high-impact technologies in the European Union. The fully-fledged EIC was launched March 2021 under Horizon Europe and i ...

also awarded the firm a £2.2 million grant.

References

Cancer screening Artificial intelligence companies Companies based in Glasgow Medical technology companies Companies established in 2016 Biotechnology companies of the United Kingdom